Status:
COMPLETED
Xarelto for VTE Prophylaxis After Hip or Knee Arthroplasty
Lead Sponsor:
Bayer
Collaborating Sponsors:
Janssen Research & Development, LLC
Conditions:
Venous Thromboembolism
Eligibility:
All Genders
18+ years
Brief Summary
The main goal is to provide additional information to the risk-benefit assessment of the drug.
Eligibility Criteria
Inclusion
- Female and male patients who will undergo elective hip or knee arthroplasty.
Exclusion
- Exclusion criteria must be read in conjunction with the local product information.
Key Trial Info
Start Date :
February 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2013
Estimated Enrollment :
19076 Patients enrolled
Trial Details
Trial ID
NCT00831714
Start Date
February 1 2009
End Date
April 1 2013
Last Update
January 23 2017
Active Locations (42)
Enter a location and click search to find clinical trials sorted by distance.
1
Many Locations, Australia
2
Many Locations, Austria
3
Many Locations, Belgium
4
Many Locations, Bosnia and Herzegovina